Biotech drug development company Durata Therapeutics is moving its global headquarters to Illinois from New Jersey, Governor Pat Quinn said Wednesday.
The company is relocating to 200 S. Wacker in Chicago from New Jersey. Quinn's office said the company expects to create 100 new jobs here in the next three years.
Durata wil get tax credits, based on job creation, that can be used against corporate income taxes, to be paid over 10 years under the Economic Opportunity for a Growing Economy (EDGE) program.
Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA® (ocriplasmin) in the USA for the treatment of Symptomatic Vitreomacular Adhesion (VMA).
Given the narrow initial public offering window, declining venture investments and tough capital markets, mergers and acquisitions (M&A) have become the exit of choice for many biopharmaceutical companies. In 2011, there were more M&As than in 2010, deal value was higher, but it still wasn't the flood of deals many industry observers had expected, according to BioWorld.
At the annual meeting of Pharmaceutical Research and Manufacturers of America (PhRMA), Christopher Viehbacher, chief executive officer of sanofi-aventis, resumed his role as board chairman, while John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Co. was elected as chairman-elect of the PhRMA Board of Directors and Robert J. Hugin, president and chief executive officer of Celgene Corp. was elected PhRMA’s board treasurer. Viehbacher assumed the chairmanship in December 2010.
West (www.westpharma.com) has expanded its family of cyclic olefin polymer (COP) products with the introduction of the Daikyo Crystal Zenith (CZ) 1-mL long insert needle syringe system. The 1-mL long format has been favored for packaging of biologics in prefilled syringes. In manufacturing at West’s Scottsdale, AZ, facility, the needle is insert-molded into the plastic syringe.
dhesives and tungsten residues—potential contaminates in glass syringes with staked needles—are avoided, says Graham Reynolds, vice president, marketing and innovation, West.
By David Vaczek, Senior Editor
Advanced parenteral delivery solutions are affording product differentiation and therapeutic benefits across a range of therapies.
In needle-based injection, cartridge-based pens and prefilled syringes loaded into disposable auto injector devices offer features that support easier self administration by patients.
Last year, Baxter’s BioPharma Solutions business (www.baxterbiopharmasolutions.com) expanded its cytotoxic contract manufacturing capacity to increase support of early-phase oncology sterile drug formulation through commercial scale-up, introduction, and lifecycle management. In need of a capacity extension, Baxter replaced a vial-filling machine with a highly automated filling line including a closed Restricted Access Barrier System (cRABS) dedicated for aseptic manufacturing of cytotoxics at its manufacturing facility in Halle (Westfalen), Germany.
Illinois Governor Pat Quinn cut the ribbon at the 2010 BIO International Convention and met with industry leaders, including executives from Vetter, a provider of aseptic prefilled drug-delivery systems.
The biomedical industry is a critical factor in California’s efforts to achieve economic recovery, according to a report by the California Healthcare Institute (CHI) and PricewaterhouseCoopers LLP.